JARDIANCE® provides triple protection in your patients with CRM conditions:
Expert's Opinion on benefits of starting A1 and A2 patients, regardless of RAASI use at baseline with empagliflozin? (Brendon Neuen)
20/08/2024 | Author: Boehringer Ingelheim
Document ID: PC-MY-103827
RELATED CONTENT
1:31
PEKP||Expert Opinion on RAASi dose optimization before addition of SGLT2i (Brendon Neuen)
1:12
PEKP||Expert's opinion video on synergistic relationship between RAASi and SGLT2i?
1:06
PEKP||Expert's Opinion on role of screening for HCPS in general (Brendon Neuen)
1:09
PEKP||Expert's opinion on starting SGLT2i in lower eGFr/eGFR dip (Brendon Neuen)
1:16
PEKP||Expert's Opinion on How is eGFR slope a viable surrogate endpoint for kidney disease progression in clinical trials? (Brendon Neuen)
1:15